---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019708"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:56:51.520413+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio: MB-106 achieves 100% complete response in follicular lymphoma in Phase 1/2

## Summary
- 100% complete response rate in 5 follicular lymphoma patients; 100% overall response in follicular and Waldenstrom macroglobulinemia.
- Favorable safety: no CRS > Grade 1, no ICANS; outpatient administration feasible.
- Complete responses seen in patients previously treated with CD19-targeted CAR-T therapy.
- Plan to finalize Phase 2 dose in early 2024; End-of-Phase 1 FDA meeting expected H1 2024.
- Registrational trial planned for relapsed/refractory WM with 58 patients; top-line data expected mid-2026.

## SEC filing metadata
- accession: 0001558370-23-019708
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023019708/0001558370-23-019708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023019708/tmb-20231211x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019708
- JSON: https://secwatch.observer/filing/0001558370-23-019708.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.